Chuangxiang Biotechnology announced the completion of the reverse merger transaction with Ikena Oncology

Zhitong
2025.07.28 11:18

On July 28, Chuangxiang Biotechnology announced the completion of a reverse merger with Ikena Oncology, Inc. The merged company has officially been renamed ImageneBio, Inc. and will be listed on the NASDAQ in the United States on July 28, 2025, with the stock code "IMA." Imagene's core asset is the OX40-targeted monoclonal antibody IMG-007, which is currently undergoing a Phase 2b clinical trial for moderate to severe atopic dermatitis. Along with this strategic upgrade, Miragene also announced its full independent operation. In addition to IMG-007, all product pipelines, cooperative projects, and resources from the "Smart Innovation" platform originally under Inmagene will be transferred to Miragene as a whole

Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.